验证数据展示
经过测试的应用
Positive IHC detected in | human kidney tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
发表文章中的应用
WB | See 1 publications below |
IHC | See 1 publications below |
产品信息
10887-1-AP targets PPT1 in WB, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.
经测试应用 | IHC, ELISA Application Description |
文献引用应用 | WB, IHC |
经测试反应性 | human, mouse, rat |
文献引用反应性 | human, mouse |
免疫原 | PPT1 fusion protein Ag1131 种属同源性预测 |
宿主/亚型 | Rabbit / IgG |
抗体类别 | Polyclonal |
产品类型 | Antibody |
全称 | palmitoyl-protein thioesterase 1 |
别名 | CLN1, INCL, Palmitoyl protein hydrolase 1, PPT, PPT 1, PPT1 |
计算分子量 | 34 kDa |
GenBank蛋白编号 | BC008426 |
基因名称 | PPT1 |
Gene ID (NCBI) | 5538 |
RRID | AB_2168906 |
偶联类型 | Unconjugated |
形式 | Liquid |
纯化方式 | Antigen affinity purification |
UNIPROT ID | P50897 |
储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
The defective gene behind the INCL(infantile neuronal ceroid lipofuscinoses) disease, CLN1, encodes for palmitoyl protein thioesterase 1 (PPT1). It consists of 306 amino acids, including a signal sequence of 26 amino acids and three N-linked glycosylation sites. This protein exsits with the molecular mass of 32 kDa, 34 kDa,36 kDa and 38 kDa. The enzyme is transported into lysosomes of non-neuronal cells by the mannose 6-phosphate receptor (M6PR) mediated pathway and a significant amount of native PPT1 resides in a complex rather than in a monomeric form(PMID:17565660).
实验方案
Product Specific Protocols | |
---|---|
IHC protocol for PPT1 antibody 10887-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |